Safety Assessment Support
From complete IND-enabling programs to stand-alone assessments, our Safety Assessment team provides a full range of in vivo and in vitro testing services and regulatory support to comply with worldwide regulatory requirements for the nonclinical development of pharmaceuticals and animal health products as well as chemicals, agrochemicals, and biocides. Our scientific and regulatory staff collaborate with clients to develop and execute individual studies or customized testing programs to ensure that drug safety and efficacy assessments are performed in the most efficient manner.
Industry Support
It is critical that you choose a partner you can trust to keep you on the path to success. We pride ourselves in exploring niche markets, staying up to date with regulatory changes, and keeping up with new technologies to support the specific testing and manufacturing requirements of regulated industries.
Meet the Team
These scientists joining from Citoxlab bring new perspectives and years of experience to our growing safety assessment team.
Philippe Ancian, PhD
Director of Biomarkers
Dr. Ancian graduated as an engineer in chemistry from the National School of Chemistry in Montpellier, France before obtaining a PhD in molecular and cellular biology from Nice University. He has spent the last 20 years in the pharma, biotech, and CRO industries where he has implemented and monitored biomarker analyses at the discovery, preclinical, and clinical stages. Philippe is passionate about advanced therapies, including immunotherapies, and cell and gene therapies.
Christian Li, BSc
Director of Toxicology, Laval, Quebec, Canada
After a BSc in biology, Chris earned a postgraduate diploma in ecotoxicology from Concordia University. He began as an auditor with Charles River Montreal’s Quality Assurance unit, working with both the validation and production QAU groups. Later as a study director, he completed more than 200 GLP and NGLP studies involving acute and chronic studies for general toxicology, inhalation, infusion, pharmacology and neurotoxicology, ocular and neuroscience, immunotoxicology, and teratology with all administration routes and species.
During this period, also served as a member of Charles River’s IACUC committee, Global In-Life Subcommittee, and harmonization projects. As the current Director of Toxicology in Laval, he oversees the site’s team of study directors, and manages sponsor interactions, study director training, study plan/amendment, data and report review, validation/method development projects, and conduct/evaluation of preclinical studies.
Simon Authier, DVM, MBA, PhD, DSP
Deputy Chief Scientific Officer
Dr. Authier has decades of experience investigating methodologies in nonclinical regulatory safety pharmacology studies to improve study designs for optimal sensitivity and decision making. He currently oversees team of scientists and veterinarians specialized preclinical research for IND, BLA, and NDA filing with a focus on pharmacology. He is frequently a speaker at major scientific conferences around the world, including the FDA, NIAID, and leading pharmacology and toxicology societies.
Simon is currently an associate professor at University of Montreal, Canada where he is involved with clinical immunology and pharmacology. He has authored more than 70 peer-reviewed publications and provided scientific overview for over 800 preclinical studies.
John Stamatopoulos, BSc
Director of Bioanalytical and Analytical Chemistry
John has over 21 years of extensive LC-MS/MS experience in preclinical and clinical contract research organizations. He currently leads a team of scientists and analysts in Bioanalytical and Analytical Chemistry, ensuring that all work is performed in compliance with general scientific/regulatory standards and in full compliance with GLP. John obtained his bachelor’s degree in biochemistry from Concordia University.
How can we support your Safety Assessment needs?
Partner with us to navigate the complex safety assessment landscape and gain access to leading scientific and regulatory expertise along with advanced preclinical solutions designed to support your program.